ANK2 as a novel predictive biomarker for immune checkpoint inhibitors and its correlation with antitumor immunity in lung adenocarcinoma

BACKGROUND: Immune checkpoint inhibitors (ICIs) have been shown to significantly improve the survival of patients with advanced lung adenocarcinoma (LUAD). However, only limited proportion of patients could benefit from ICIs. Novel biomarkers with strong predictability are needed for clinicians to m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wengang, Shang, Xiaoling, Liu, Ni, Ma, Xinchun, Yang, Rui, Xia, Handai, Zhang, Yuqing, Zheng, Qi, Wang, Xiuwen, Liu, Yanguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768990/
https://www.ncbi.nlm.nih.gov/pubmed/36539782
http://dx.doi.org/10.1186/s12890-022-02279-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768990/
https://www.ncbi.nlm.nih.gov/pubmed/36539782
http://dx.doi.org/10.1186/s12890-022-02279-2

Ejemplares similares